Leukemia

Among patients with newly diagnosed, chronic-phase chronic myeloid leukemia, a lower-dose regimen of radotinib demonstrated superior complete cytogenetic response and major molecular response rates at 12 months compared to imatinib.

Achievement of event-free survival at 24 months is highly predictive of overall survival in patients with peripheral T-cell lymphomas, according to a new study.

A novel risk classification scheme based on expression of 36 micro-RNA samples was able to identify pediatric patients with acute myeloid leukemia at high or low risk of experiencing treatment failure, according to a new analysis.

Older patients with acute myeloid leukemia had substantial misperceptions regarding the risks of their treatment, whether intensive or palliative chemotherapy, and the likelihood of cure.

In patients with chronic myeloid leukemia treated with bosutinib who were resistant or intolerant to previous tyrosine kinase inhibitors, health-related quality of life was well maintained over the long term.

In this interview with Jorge Cortes, MD, he discusses why gemtuzumab ozogamicin is experiencing a comeback for the treatment of patients with acute myeloid leukemia.

Abbreviated chemotherapy is as effective as a full course in patients with chronic lymphocytic leukemia who achieve early minimal residual disease–negative complete responses.

Characteristics of the diabetic intrauterine environment may promote the development of acute lymphoblastic leukemia in offspring, according to the results of a new study.

Researchers have created a chimera virus that they believe may have the ability to disable certain lymphomas, paving the way for new treatment options.

A study by German investigators is elucidating the role of tyrosine kinase inhibitors in targeting FLT3 in acute myeloid leukemia.

About one in every 25 patients with chronic lymphocytic leukemia had abnormal liver function tests, and one in four developed liver dysfunction within 10 years, according to the results of a retrospective study.

A new study found significant gaps in the monitoring of responses to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Patients are more likely to be monitored in Europe, at academic centers, and if they are younger than 65.

Treatment with tyrosine kinase inhibitors for chronic myeloid leukemia is risky for pregnant patients, according to a new study, with the potential for congenital malformations in the baby.

HLA-mismatched microtransplant offers good complete remission rates in older patients with acute myeloid leukemia, according to a new study.

The FDA has approved gemtuzumab ozogamicin (Mylotarg) for the first-line treatment of adults with CD33-positive AML and for pediatric patients with relapsed or refractory CD33-positive AML.

A new study found that lenalidomide was effective as a maintenance therapy after first-line treatment in patients with chronic lymphocytic leukemia who did not achieve minimal residual disease negative status after chemoimmunotherapy approaches.

Researchers have discovered a three-drug combo that may combat acute lymphoblastic leukemia by shutting down the production of nucleotides that activate a DNA replication stress response.

Anti-CD19 chimeric antigen receptor (CAR)-modified T-cell therapy was highly effective in patients with high-risk chronic lymphocytic leukemia who had previously failed treatment with ibrutinib.

This video highlights patient variables, including kidney function or history of diabetes, that can help guide treatment in chronic myeloid leukemia.

The FDA has approved the first gene therapy available in the United States, tisagenlecleucel (Kymriah), for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Natural killer cells derived from donated umbilical cords could be modified to seek and destroy some types of leukemia and lymphoma.

In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma.

Pediatric patients with ALK-positive anaplastic large cell lymphomas and inflammatory myofibroblastic tumors had strong responses to treatment with crizotinib.

The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Pediatric solid organ transplant recipients account for about 3% of diagnosed pediatric non-Hodgkin lymphoma cases in the United States.

Arsenic trioxide consolidation was well tolerated in pediatric patients with acute promyelocytic leukemia and allowed for significant reductions in cumulative anthracycline doses.

Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study.

The FDA has approved a fixed combination of daunorubicin and cytarabine (Vyxeos) for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) as well as AML with myelodysplasia-related changes.

Patients with primary immunodeficiency diseases are at increased risk of certain cancers, according to a new study. The strongest association was with lymphoma.

Acalabrutinib has been granted FDA Breakthrough Therapy Designation for the treatment of patients with mantle cell lymphoma who have relapsed or have received at least one prior therapy.